Are we entering a new era for patients and clinicians?

My guest for this special episode recorded live at the 15th Annual Congress on Controversies in Ophthalmology (COPHy) is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at University of Manchester, United Kingdom. In this episode, Tariq and I discuss whether the introduction of next generation therapies for the clinical management of retinal diseases will open the door to a new era for patients and clinicians.We also consider how learnings from the Barometer Global Survey surrounding the multiple challenges associated with management of retinal diseases can be implemented into clinical practice, and touch on how we can best support our patients to achieve extended treatment intervals.If you want to know more about the Barometer Program’s Global Survey, or the Barometer’s efforts towards patient-focused care, visit our website: https://www.amdbarometer.org/. Also on the website are important materials resources to help you in your clinical practice (such as communication guides and educational materials) and to help your patients (such as information packs for patients to give to their employers). If you enjoyed this episode, please listen to past episodes in this series to hear retinal experts discussing how to choose the optimal anti-VEGF therapy regimen for patients with retinal vascular diseases, how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence, and how we as ophthalmologists can both understand and help patients with the burden of treatment. SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!Further information on content in other podcasts in this series can be found at: https://www.amdbarometer.org/resources This podcast was produced in association with the Vision Academy; viewpoints on clinically challenging situations, educational slide decks, video content and other materials, can be found at the Vision Academy, https://www.visionacademy.org/. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.Speaker disclosures:Professor Anat LoewensteinConsultancy: Allergan, Annexon, Bayer, Beyeonics, Biogen, ForSight Labs, Iqvia, Iveric Bio, Johnson & Johnson, MJHEvents, Nanoretina, Notal Vision, Novartis, Ocuphire Pharma, Ocuterra, Ophtimedrx, Ripple Therapeutics, Roche, Syneos, WebMD, and Xbrane. Professor Tariq Aslam Grants/Speaker fees: Bayer, Canon, Heidelberg, Novartis, and Roche. March 2026 | PP-PF-OPHT-ALL-0163-1This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.This podcast series is produced and funded by Bayer Consumer Care AG. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer Consumer Care AG. The activities of the Barometer Program are funded and facilitated by Bayer Consumer Care AG where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer Consumer Care AG. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer Consumer Care AG.